Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Genitourinary 2Dermatologic 2Breast 2Thoracic 1Other solid neoplasm 1Head & Neck 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 16Uterine Cervical Neoplasms 8Melanoma 7Colorectal Neoplasms 7Fallopian Tube Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 5Breast Neoplasms 5Recurrence 4Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Ovarian Epithelial 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Prostatic Neoplasms 2Neoplasms 2Lymphoma 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Vaginal Neoplasms 1Uterine Cervical Dysplasia 1Turcot syndrome 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

pembrolizumab 17Carboplatin 10Paclitaxel 7Trastuzumab 5Nivolumab 5Gemcitabine 5Early Intervention, Educational 5Cyclophosphamide 5Cisplatin 5fludarabine 4cemiplimab 4Psychiatric Rehabilitation 4Fluorouracil 4Docetaxel 4Counseling 4Albumin-Bound Paclitaxel 4tisotumab vedotin 3belinostat 3Radiotherapy 3Polymerase Chain Reaction 3Methods 3Magnetic Resonance Spectroscopy 3Gene Expression Profiling 3Fluorodeoxyglucose F18 3Biopsy 3zimberelimab 2ulixertinib 2pertuzumab 2palbociclib 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Interleukin-2 × Gynecologic × Clear all
NCT05086692 2025-07-09

ABILITY-1

Medicenna Therapeutics, Inc.

Phase 1/2 Recruiting
115 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02153905 2019-06-17

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 14 charts
BreastDermatologicGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡